Drug Therapy in Atrial Fibrillation Management: Where Do We Stand in 2010? trial of atrial fibrillation investigators. N Engl J Med 2000;342:913- 920. 34. Kochiadakis GE, Igoumenidis NE, Marketou ME, Solomou MC, Kanoupakis EM, Vardas PE. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1998;81:995-998. 35. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50. 36. Manning AS, Bruyninckx C, Ramboux J, Chatelain P. SR 33589, a new amiodaronelike agent: effect on ischemia- and reperfusion- induced arrhythmias in anesthetized rats. J Cardiovasc Pharmacol 1995;26:453-461. 37. Idem. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol 2002;39:677-684. 38. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH; EURIDIS and ADONIS investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357:987-999. 39. Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crijns H, Amlie J, Carlsen J; Dronedarone study group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-2687. 40. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-678. 41. Arya A, Silberbauer J, Teichman SL, Milner P, Sulke N, Camm AJ. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace 2009;11:458-464. 42. Singh J, Braich JS. Recent advances in pharmacotherapy of atrial fibrillation. Indian J Pharmacol 2009;41:153-157. 43. Gautier P, Serre M, Cosnier-Pucheu S, Djandjighian L, Roccon A, Herbert JM, Nisato D. In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias. J Cardiovasc Pharmacol 2005;45:125-135. 44. Bernard EO, Schmid ER, Schmidlin D, Scharf C, Candinas R, Germann R. Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study. Crit Care Med 2003;31:1031- 1034. 45. Giudici MC, Fischer WJ 3rd, Cervantes DC, Schrumpf PE, Paul DL, Sentman KE, Serra VL, Barold SS. Ibutilide therapy for atrial fibrillation: 5-Year experience in a community hospital. J Cardiovasc Nurs 2008;23:484-488. 46. Torp-Pedersen C, Moller M, Kober L, Camm AJ. Dofetilide for the treatment of atrial fibrillation in patients with congestive heart failure. Eur Heart J 2000;21:1204-1206. 47. Banchs JE, Wolbrette DL, Samii SM, Penny-Peterson ED, Patel PP, Young SK, Gonzalez MD, Naccarelli GV. Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter. J Interv Card Electrophysiol 2008;23:111-115. 48. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007;116:1449-1457. 49. Pratt CM, Singh SN, Al-Khalidi HR, Brum JM, Holroyde MJ, Marcello SR, Schwartz PJ, Camm AJ; ALIVE investigators. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction results from the azimilide postinfarct survival evaluation (ALIVE) trial. J Am Coll Cardiol 2004;43:1211-1216. 50. Hohnloser SH, Dorian P, Straub M, Beckmann K, Kowey P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J Am Coll Cardiol 2004;44:99-104. TEHRAN HEART CENTER 51. Guerra JM, Everett TH 4th, Lee KW, Wilson E, Olgin JE. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation 2006;114:110- 118. 52. Nattel S, Matthews C, De Blasio E, Han W, Li D, Yue L. Dosedependence of 4-aminopyridine plasma concentrations and electrophysiological effects in dogs: potential relevance to ionic mechanisms in vivo. Circulation 2000;101:1179-1184. 53. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007;116:1449-1457. 54. Fedida D, Orth PM, Chen JY, Lin S, Plouvier B, Jung G, Ezrin AM, Beatch GN. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2005;16:1227-1238. 55. Dorian P, Pinter A, Mangat I, Korley V, Cvitkovic SS, Beatch GN. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol 2007;50:35-40. 56. Roy D, Rowe BH, Stiell IG, Coutu B, Ip JH, Phaneuf D, Lee J, Vidaillet H, Dickinson G, Grant S, Ezrin AM, Beatch GN; CRAFT investigators. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004;44:2355-2361. 57. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ; Atrial arrhythmia conversion trial investigators. RSD1235 for conversion of atrial fibrillation. The phase III atrial arrhythmia conversion trial. Circulation 2008;117:1518-1525. 58. Cheng JW. Vernakalant in the management of atrial fibrillation. Ann Pharmacother 2008;42:533-542. 59. Goldstein RN, Khrestian C, Carlsson L, Waldo AL. AZD7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 2004;15:1444-1450. 60. Duker G, Bj¨orkman JA, Linhardt G, Carlsson L: AZD7009: A new antifibrillatory compound that markedly delays atrial refractoriness in the anesthetised dog. Heart Rhythm 2004;1:S159. 61. Crijns HJ, Van Gelder IC, Walfridsson H, Kulakowski P, Rónaszéki A, Dedek V, Malm A, Almgren O. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm 2006;3:1321-1331. 62. Morita N, Tanaka K, Yodogawa K, Hayashi M, Akutsu K, Yamamoto T, Satoh N, Kobayashi Y, Katoh T, Takano T. Effect of nifekalant for acute conversion of atrial flutter: the possible termination mechanism of typical atrial flutter. Pacing Clin Electrophysiol 2007;30:1242-1253. 63. Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, Calkins H, Connolly SJ, Curtis AB, Darbar D, Ellinor PT, Go AS, Goldschlager NF, Heckbert SR, Jalife J, Kerr CR, Levy D, Lloyd-Jones DM, Massie BM, Nattel S, Olgin JE, Packer DL, Po SS, Tsang TS, Van Wagoner DR, Waldo AL, Wyse DG. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation 2009;119:606-618. 64. Kalus JS. Angiotensin inhibitors prevent atrial fibrillation after cardiothoracic surgery. J Am Coll Cardiol 2008;51:A15. 65. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL; American heart association/American stroke association stroke council; Atherosclerotic peripheral vascular disease interdisciplinary working group; Cardiovascular nursing Council; clinical cardiology council; Nutrition, physical activity, and metabolism council; Quality of care and outcomes research interdisciplinary working group; American academy of neurology. Primary prevention of ischemic stroke: a guideline from the American heart association/ American stroke association stroke council: cosponsored by the The Journal of Tehran University Heart Center177